Veru announces the presentation of updated data from the phase 1b/2 sabizabulin study in men with metastatic castration resistant prostate cancer at the 2022 asco genitourinary cancers symposium

Miami, feb. 17, 2022 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that updated clinical data from the positive phase 1b/2 study of sabizabulin in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent will be presented at the 2022 asco genitourinary cancers symposium being held february 17-19, 2022 in san francisco, ca. sabizabulin is an oral new chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt the cytoskeleton.
VERU Ratings Summary
VERU Quant Ranking